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Open access under CC BWe herein report a faster and less cumbersome synthesis of the biologically attractive, a-galactosyl cer-
amide (a-GalCer), known as KRN7000, and its analogues. More importantly, the use of a silicon tethered
intramolecular glycosylation reaction gave easy access to the diglycosyl ceramide Gal(a1?2)GalCer,
which has been shown to require uptake and processing to the biologically active a-GalCer derivative.
 2009 Elsevier Ltd. Open access under CC BY license.CD1d is a nonpolymorphic glycoprotein expressed on the sur-
face of antigen-presenting cells (APCs). It is speciﬁcally associated
with presenting lipid antigens that activate the distinctive class of
T cells, known as invariant Natural Killer T (iNKT) cells. iNKT cells
display characteristics of both T cells and NK cells and play a cru-
cial role in diverse immune responses and other pathologic condi-
tions.1–4 When the synthetic glycolipid a-galactosyl ceramide (a-
GalCer),5 known as KRN7000 (1), is bound to CD1d and presented
to the T cell receptors (TCRs) on the surface of iNKT cells, the latter
are activated to release diverse cytokines, including both Th1 and
Th2 cytokines.6–8 It is believed that the release of Th1 cytokines
may contribute to antitumour and antimicrobial functions while
that of Th2 cytokines may help alleviate autoimmune diseases9–
11 such as multiple sclerosis12 and arthritis.13 a-GalCer and its
derivatives have proved to be and remain invaluable tools in
understanding the functioning of CD1d and NKT cells in a wide
range of immune responses. As part of various ongoing studies,
easy access to relatively extensive quantities of these substrates
is, therefore, required.Y license.O
HO
HO
HO
OH
C14H29
O
NH
OH
OH
C25H51O O
HO
HO
HO
OH
C14H29
O
NH2
OH
OH
1 2
Several elegant syntheses of a-GalCer are present in the litera-
ture.14 Most of these syntheses make use of benzyl ether protecting
groups on the sugar moiety. We, along with many other research
groups, have encountered difﬁculties in the hydrogenolysis of ben-
zyl ethers, thereby leading to low yields of a-GalCer. Therefore,
synthetic routes circumventing the problematic hydrogenolysis
step are highly desired. Kiso and co-workers15 recently reported
such a synthesis, where interestingly they also made use of the
bulky 4,6-O-di-tert-butylsilylene (DTBS) group as a-directing in
galactosylation donor 3.O
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Scheme 3. Reagents and conditions: (a) PhSH, DMF, Cs2CO3, 75%; (b) (CH3)2Si(Cl)2,
Pyridine, CH2Cl2, quant; (c) 5, Pyridine, DMF, 72%; (d) NIS, CH3NO2, 66%; (e) NaOMe/
MeOH, quant; (f) H2, Pd/C, MeOH, 80%; (g) C25H51COCl, THF, NaOAc, 75%.
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that of Kiso and co-workers to obtain the glycosylated sphingoid
base template 2, which can readily be converted to a-GalCer and
other derivatives. Initially, to improve on the reported synthesis
we resorted to the use of the thioglycosyl donor 4 as it is easier
to handle and has a better shelf life than the trichloroacetimidate
donor 3. Signiﬁcantly, the second route describes a novel synthesis
of a-GalCer and has the additional beneﬁt of providing a crucial
intermediate, which can be further modiﬁed to yield other biolog-
ically active a-GalCer derivatives.
We ﬁrst synthesized the phytosphingosine acceptor 516 from
(2S,3S,4R)-2-azido-1, 3, 4-octadecanetriol17 in three steps as de-
scribed in Scheme 1.
The thioglycoside 4 was obtained in large scale from commer-
cially available b-D-galactopyranose pentaacetate after standard
procedures, as described previously.18The critical glycosylation
was then attempted on 2 g of the donor 4. NIS/TfOH activation18,19
of thioglycoside 4 (Scheme 2) in anhydrous CH2Cl2 at 78 C affor-
ded the glycosylated compound 6 in 71% yield, as the a-anomer
exclusively after two hours. Subsequent sequential removal of
the silyl group with TBAF and Zemplen’s deprotection of the ben-
zoate protecting groups produced the azide intermediate in quan-
titative yields after puriﬁcation by ﬂash chromatography. Different
methods for the reduction of the azide group were attempted,
including the use hydrogen sulﬁde, but the best results were ob-
tained via hydrogenation in methanol. 800 mg of the amine 2
was hence isolated as a white solid.HO C14H29
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Scheme 1. Reagents and conditions: (a) TBDPSCl, Pyr, quant; (b) BzCl, Pyr, 88%; (c)
TBAF, THF, 82%.
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Scheme 2. Reagents and conditions: (a) NIS/TfOH, CH2Cl2, 67%; (b) TBAF, THF,
quant; (c) NaOMe/MeOH, 92%; (d) H2, Pd, 88%.Scheme 3 illustrates our novel strategy to synthesise a-GalCer
and its derivatives. Silicon tethered intramolecular glycosylation20
is a particularly attractive method for generating glycosidic bonds
stereoselectively, but not attempted by many research groups due
to the difﬁculty in handling and relative instability of the silylene-
tethered sugar derivative. However, successful examples have
been reported and we were motivated by Bols21 work on the syn-
thesis of disaccharides containing a-galactosyl linkages. Hence, 3,
4, 6-tri-O-acetylgalactopyranosyl chloride (7)22 was obtained from
b-D-galactopyranose pentaacetate and converted to the corre-
sponding thioglycoside 8 by reacting with thiophenol in the pres-
ence of caesium carbonate. The tethered compound 9 was then
synthesised following the procedure described by Bols.21 Rear-
rangement of the silylene 9, catalyzed by N-iodosuccinimide
(NIS) in anhydrous nitromethane at 80 C,21 yielded the desired
product 10 along with some small amounts of 5 after 2 h. It was
observed that by careful monitoring and quenching of the reaction
as soon as compound 9 was consumed, helped in minimizing the
regeneration of phytosphingosine derivative 5 and hence enhanced
the yield of the glycosylated product. Methanolysis, followed by
hydrogenation of the azide then afforded compound 2. Finally, N-
acylation with the fully saturated fatty acid, hexacosanoic acid,
was achieved via reaction of the corresponding acid chloride with
the free amine 2 in a 1:1 mixture of THF and saturated sodium ace-
tate solution. Target compound 1 was obtained as a white solid
after concentration of the organic phase and puriﬁcation of the res-
idue by ﬂash chromatography. The spectroscopic data of the latter
were consistent with the literature.14
While our ﬁrst approach (Scheme 2) is more direct and higher
yielding, the alternative route (Scheme 3) also provides the addi-
tional beneﬁt of freeing the hydroxyl group at C-2 on the sugar res-
idue (compound 10). This allows for selective modiﬁcation on a-
GalCer; such as the introduction of an additional sugar residue.
Speciﬁcally, the diglycosyl ceramide, Gal(a1?2GalCer) 12 has
been used to study lysosomal glycolipid processing.23 Brieﬂy,
galactosidases from lysosomes are responsible for truncating oligo-
glycosyl ceramides to monoglycosyl ceramides before they can
bind to CD1d and be presented to iNKT cells.23 Scheme 4 depicts
a new strategy for synthesizing disaccharide 11 via NIS/TfOH acti-
vation of sugar donor 4 at 78 C in anhydrous CH2Cl2 for 3 h. Once
more, the directing effect of the bulky silyl group ensured the for-
mation of the desired a-linkage, as conﬁrmed by the H-1 and C-1
signals in 1H and 13C NMR. Compound 12 was obtained after rou-
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Scheme 4. Reagents and conditions: (a) NIS/TfOH, CH2Cl2, 67%; (b) TBAF, THF,
quant; (c) NaOMe/MeOH, quant; (d) H2, Pd, MeOH, 80%; (e) C25H51COCl, THF,
NaOAc, 78%.
Figure 1. a-GalCer and Gal(a1?2GalCer) stimulate CD1d-restricted iNKT cells. (a)
In vitro activation of 2.5  104 human iNKT cells (clone BM2a.3) in co-culture with
2.5  104 U937 cells and various concentrations of a-GalCer (ﬁlled squares) and
Gal(a1?2GalCer) (open squares). After 16 h, cytokines were determined in culture
supernatants by ELISA; (b) in vitro activation of 5  104 mouse iNKT cells
(hybridoma DN32) in co-culture with 5  104 RAW cells transfected with CD1d
(ﬁlled symbols) or untransfected (open symbols) and various concentrations of a-
GalCer (squares) and Gal(a1?2GalCer) (circles). After 16 h, cytokine concentrations
were determined in culture supernatants by ELISA; (c) Plate-bound murine
recombinant CD1d-Fc fusion proteins were loaded with a-GalCer (ﬁlled squares)
or Gal(a1?2GalCer) (open squares) for 16 h, washed, and 5  104 iNKT cell
hybridomas were added per well. Cytokines were determined in culture superna-
tants by ELISA; (d) RAW cells transfected with CD1d were pulsed with 100 ng/ml of
a-GalCer or Gal(a1?2GalCer) for 3 h and then washed and ﬁxed with glutaralde-
hyde (ﬁlled bars), or ﬁxed and then pulsed for 3 h (open bars). 105 APCs were co-
cultured with 105 iNKT cell hybridomas for 16 h and cytokines were determined in
culture supernatants by ELISA. Cytokine responses are expressed as percent of
maximal response. Methods are described elsewhere.25
4290 N. Veerapen et al. / Bioorg. Med. Chem. Lett. 19 (2009) 4288–4291tine procedures, similar to those described above and exhibited
spectroscopic data consistent with the literature.24
We next tested the biological activity of a-GalCer and
Gal(a1?2GalCer). Both lipids stimulated human and mouse iNKT
cells in the presence of CD1d-expressing antigen-presenting cells
(APC) (Fig. 1a and b). a-GalCer, but not Gal(a1?2GalCer), stimu-
lated iNKT cells in an APC-free CD1d-Fc fusion protein plate assay
(Fig. 1c). In ﬁx/pulse, pulse/ﬁx experiments a-GalCer stimulated an
iNKT cell response under both conditions, whereas Gal(a1?2Gal-
Cer) resulted in cytokine release only under the pulse/ﬁx condition
(Fig. 1d). Together, these data suggest that a-GalCer and
Gal(a1?2GalCer) described here can stimulate human and mouse
iNKT cells. Furthermore, Gal(a1?2GalCer), in contrast to a-GalCer,
required uptake and processing to generate the biologically active
monoglycosyl ceramide.
In conclusion, we have demonstrated the versatility of both
compounds 4 and 10 as crucial intermediates in practical and
high-yielding syntheses of a-GalCer and other biologically impor-
tant derivative, such as Gal(a1?2GalCer).26
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